Darvishi, Ali; Daroudi, Rajabali; Fazaeli, Ali Akbar - In: Health economics review 13 (2023) 1, pp. 1-13
Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC). The objective of this study was to...